Related Experiment Video
Updated: May 3, 2026
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
The ergogenic effect of long-term use of high dose salbutamol
John Dickinson1, John Molphy, Neil Chester
1*Endurance Research Group, School of Sport and Exercise Sciences, University of Kent, Kent, United Kingdom; †Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom; and ‡English Institute of Sport, Institute of Sport Exercise and Health, University College London, London, United Kingdom.
Objective:
Investigate the effect of inhaling 1600 μg salbutamol for 6 weeks on endurance, strength, and power performances.
Design:
Randomized double-blind, mixed-model repeated measures.
Participants:
Sixteen male athletes (mean ± SD: age, 20.1 ± 1.6 years; height, 179.9 ± 8.2 cm; weight, 74.6 ± 9.1 kg).
Interventions:
Participants were assigned to either a placebo inhaler (PLA) or inhaled 1600 μg salbutamol group (SAL). Over 6 weeks, participants inhaled PLA or SAL and completed 4 training sessions per week that focused on endurance, strength, and power.
Main Outcome Measures:
Participants completed the assessments of peak oxygen consumption (V[Combining Dot Above]O2peak), 3-km time trial, vertical jump height, 1 repetition maximum (1RM) bench and leg press, and peak torque knee flexion and extension. Assessments were undertaken at baseline, week 3, and week 6.
Results:
Over the 6 weeks, PLA and SAL groups improved V[Combining Dot Above]O2peak (51.7 ± 4.7 vs 56.8 ± 7.1 mL·min·kg; 53.1 ± 6.1 vs 55.0 ± 6.7 mL·min·kg); 3-km running time trial (988.6 ± 194.6 vs 947.5 ± 155.5 seconds; 1040.4 ± 187.4 vs 1004.2 ± 199.4 seconds); 1RM bench press (65.7 ± 15.4 vs 70.3 ± 13.8 kg; 64.3 ± 14.0 vs 72.5 ± 15.3 kg); and leg press (250.0 ± 76.4 vs 282.5 ± 63.6 kg; 217.9 ± 54.0 vs 282.8 ± 51.9 kg). The SAL group did not improve significantly greater in any endurance or strength and power measure when compared with the PLA group.
Conclusions:
Inhaling 1600 µg salbutamol daily over 6 weeks does not result in significant improvements in endurance, or strength and power performances.
Clinical Relevance:
Athletes using inhaled salbutamol to treat bronchoconstriction during exercise on a daily basis will not gain an advantage over nonasthmatic athletes not using inhaled salbutamol.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:20Desensitization and Tachyphylaxis
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Dose-Response Relationship: Selectivity and Specificity